Ads
related to: ofloxacin 0.3% oph soln 5ml drops treatment
Search results
Results From The WOW.Com Content Network
Nepafenac, sold under the brand name Nevanac among others, is a nonsteroidal anti-inflammatory drug (NSAID), usually sold as a prescription eye drop 0.1% solution (Nevanac) or 0.3% solution (Ilevro). It is used to treat pain and inflammation associated with cataract surgery. [ 3 ]
Gatifloxacin is currently available in the US and Canada only as an ophthalmic solution. [citation needed] In 2011, the Union Health and Family Welfare Ministry of India banned the manufacture, sale, and distribution of gatifloxacin because of its adverse side effects. [8] In China, gatifloxacin is sold in tablet as well as in eye drop ...
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) [2] marketed in the US as an ophthalmic solution (brand names Prolensa and Bromday, [3] prior formulation brand name Xibrom, which has since been discontinued) by ISTA Pharmaceuticals for short-term, local use. Prolensa and Bromday are the once-daily formulation of bromfenac, while ...
Tobramycin/dexamethasone, sold under the brand name Tobradex, is a fixed-dose combination medication in the form of eye drops and eye ointment, marketed by Alcon. [1] [2] [3] The active ingredients are tobramycin (an antibiotic) and dexamethasone (a corticosteroid). [2] It is prescribed for the treatment of pink eye in combination with ...
Saline solution for irrigation. Normal saline (NSS, NS or N/S) is the commonly used phrase for a solution of 0.90% w/v of NaCl, 308 mOsm/L or 9.0 g per liter. Less commonly, this solution is referred to as physiological saline or isotonic saline (because it is approximately isotonic to blood serum, which makes it a physiologically normal solution).
Bimatoprost/timolol, sold under the brand name Ganfort, is a medication for the treatment of certain conditions involving high pressure in the eyes, specifically open angle glaucoma and ocular hypertension. [1] [3] It is available as eye drops. [1] [3] It was approved for medical use in the European Union in May 2006. [3]